Last one was undersubscribed with - options expiring Aug 2011, exercise 15c.
Maybe management have learnt something.
This one oversubscribed with options expiring 2016, exercise 9c.
Higher price for shares but a much, much better deal on options. If they had offered that last time I wonder if the uptake would have been substantially more ?
Anyway, these bucks should see them funded for quite awhile, along with the income they are deriving from the research.
I will be interested to see the figure from Roche - next quarterly perhaps ?
Q. where will these new shares be traded - ASX, Frankfurt ?
(did we get a NASDAQ listing ? (-:)
I never did quite understand where shares came from to trade on the Frankfurt exchange.
share placement
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
-0.003(1.39%) |
Mkt cap ! $839.8M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $447.6K | 2.497M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 441308 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 563444 | 13 |
View Market Depth
| Last trade - 14.52pm 30/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |